Aptahem AB (publ) (NGM:APTA)

Market Cap	25.90M
Revenue (ttm)	2.80M
Net Income (ttm)	-6.58M
Shares Out	17.26M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,506
Average Volume	80,681
Open	1.620
Previous Close	1.600
Day's Range	1.550 - 1.620
52-Week Range	0.560 - 4.500
Beta	0.45
RSI	53.56
Earnings Date	Aug 28, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.